目的探讨复发转移乳腺癌患者血清HER-2浓度与组织HER-2表达水平的一致性。方法应用ELISA法测定血清HER-2浓度;应用免疫组化(IHC)法检测乳腺癌组织HER-2表达水平;对检测结果进行统计分析。结果组织HER-2阳性的复发转移乳腺癌患者中有62例血清HER-2阳性,阳性符合率为74.7%,组织HER-2阴性的患者有96例血清HER-2为阴性,阴性符合率为82.1%。血清HER-2水平与组织HER-2表达状态呈正相关(kappa=0.653,P<0.01)。结论复发转移乳腺癌患者血清HER-2浓度与组织HER-2表达水平无显著差别,两种检测方法具有较好的一致性,血清HER-2浓度可作为临床个体化治疗的参考依据。 Objective To investigate the consistency of serum HER-2 concentration and HER-2 expression in patients with recurrent breast cancer. Methods The serum concentration of HER-2 was detected by ELISA. The expression of HER-2 in breast cancer tissues was detected by immunohistochemistry (IHC) method. The results were statistically analyzed. Results The positive rate of coincidence of HER-2 positive HER-2 positive breast cancer patients was 62.7%, the positive coincidence rate was 74.7%, the negative rate of HER-2 in 96 HER-2 negative tissues was negative, the negative coincidence rate was 82.1%. The level of HER-2 in serum was positively correlated with the expression of HER-2 (kappa = 0.653, P <0.01). Conclusion There is no significant difference between the serum HER-2 levels and HER-2 expression levels in patients with recurrent and metastatic breast cancer. The two detection methods have good consistency. Serum HER-2 concentration can serve as a reference for clinical individualized treatment.